The Plasmodium falciparum Drugome And Its Polypharmacological Implications
Yinliang Zhang, Li Xie, Lei Xie, Philip E. Bourne · bioRxiv (Cold Spring Harbor Laboratory) · 2016
ABSTRACT Malaria is a disease contracted by over 200 million people each year, mostly in developing countries. The primary causative agent, Plasmodium falciparum ( P. falciparum ) has shown increased resistance to existing drugs, hence new treatments are needed quickly. To this end we performed a high-throughput systems-level analysis, mapping existing FDA drugs with the potential for repurposing against targets from the P. falciparum structural proteome. The resulting P. falciparum drugome ( P.falciparum -drugome) was used to prioritize potential new anti-malaria candidate targets and highlight some novel FDA approved drugs that have apparent anti-malaria effects for possible use as multi-target therapeutics.